Combined chemotherapy and immunotherapy shows promise for advanced prostate cancers

Google+ Pinterest LinkedIn Tumblr +

prostate sex lifeChemotherapy can be very effective against small prostate tumours.

Larger prostate tumours, however, accumulate cells that suppress the body’s immune response, allowing the cancer to grow despite treatment. Researchers at the University of California, San Diego School of Medicine now find that blocking or removing these immune-suppressing cells allows a special type of chemotherapy—and the immune cells it activates—to destroy prostate tumours. This novel combination therapy, termed chemoimmunotherapy, achieved near complete remission in mouse models of advanced prostate cancer.

The study was published April 29 in Nature.

Advanced or metastatic prostate cancer does not typically respond to chemotherapy. Prostate cancers also fail to respond to a promising new type of immunotherapy drugs, called checkpoint inhibitors, which disable cancer cells’ cloaking mechanism so that a person’s own immune system can better fight the tumour. This specific resistance is likely due in part to immunosuppressive B cells, which are more common in larger prostate tumours in mice, as well as in advanced and metastatic prostate cancer in humans. As the name suggests, these cells keep the immune system at bay, rendering most therapies ineffective and allowing malignant tumours to grow unchecked.

mice obesity styudy oncology news australiaIn this study, researchers worked with three different mouse models of advanced prostate cancer. All three models were resistant to low doses of the chemotherapy drug oxaliplatin, which has the unique ability to activate cancer-killing immune cells. But when the researchers blocked the development or function of immunosuppressive B cells or removed them entirely before treating the mice with low-dose oxaliplatin, the prostate tumours were almost completely destroyed by the mice’s own immune cells. The team got similar results when low-dose oxaliplatin was combined with a checkpoint inhibitor.

“The presence of such B cells in human prostate cancer calls for clinical testing of this novel therapeutic approach,” said Shabnam Shalapour, PhD, postdoctoral researcher and first author of the study.

“In addition to prostate cancer, similar immunosuppressive B cells can be detected in other human cancers,” said senior author Michael Karin, PhD, Distinguished Professor of Pharmacology and Pathology at UC San Diego. “This indicates that B cell-mediated immunosuppression might be the reason several other cancers are also unresponsive to checkpoint inhibitors, raising the hope that chemoimmunotherapy will have broader applications for many cancer types.”

[hr]

Journal Reference: Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy, NatureDOI: 10.1038/nature14395

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Comments are closed.